A composition for repairing vaginal mucosa and increasing vaginal elasticity, and its preparation method and application

Through the composition of yeast β-glucan, isomaltose oligosaccharide and sodium hyaluronate, the problem of difficulty in repairing the mucosa of vaginitis is solved, the repair and elastic recovery of the vaginal mucosa is achieved, and the treatment effect is significantly improved.

CN116747239BActive Publication Date: 2024-11-15HUNAN TIANGENLE WEIJUN TECH CO LTD
View PDF 5 Cites 0 Cited by

Patent Information

Application Number
CN202310951305.X
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2023-07-31
Publication Date
2024-11-15
Estimated Expiration
2043-07-31

AI Technical Summary

Technical Problem

The prior art is difficult to effectively repair the vaginal mucosa when treating vaginitis, resulting in a long treatment cycle or difficulty in eradicating, and there are problems with side effects and high recurrence rates.

Method used

Using a composition of yeast β-glucan, isomaltose and sodium hyaluronate, the combination of yeast β-glucans of different molecular weights penetrates into the epidermis, maintains moisture, forms a protective film, enhances the function of the skin barrier, and promotes A composition of cell repair and vaginal elasticity.

Benefits of technology

Effectively repair the vaginal mucosa, restore vaginal elasticity, reduce inflammation and discomfort, significantly improve the treatment effect of vaginitis, and has obvious effect on gynecological diseases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure SMS_1
    Figure SMS_1
  • Figure SMS_2
    Figure SMS_2
  • Figure SMS_3
    Figure SMS_3
Patent Text Reader

Abstract

The present invention discloses a composition for repairing vaginal mucosa and increasing vaginal elasticity, and a preparation method and application thereof, wherein the composition comprises 0.5 to 3 parts of yeast β-glucan, 0.2 to 1 parts of isomaltooligosaccharide and 0.1 to 0.8 parts of sodium hyaluronate by weight. The vaginal repair composition prepared by the present invention can be efficiently used for the treatment of gynecological diseases, and has obvious effects on the treatment of various gynecological diseases such as vaginitis, cervical erosion, vaginal mucosal repair, and vaginal elasticity repair.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of pharmaceutical chemicals and medical devices, and specifically relates to a composition for repairing vaginal mucosa and increasing vaginal elasticity, and a preparation method and application thereof. Background Art

[0002] Vaginitis, or vaginal inflammation, is a group of diseases that cause vulvar and vaginal symptoms such as itching, burning pain, irritation, and abnormal fluid discharge, affecting women's physical and mental health. Its onset is often related to the imbalance of the patient's vaginal microecology, and the treatment effect is poor and the recurrence rate is high. Its main pathological change is the imbalance of the vaginal flora, that is, the imbalance of the microecological flora that normally parasitizes in the vagina. The reduction of beneficial bacteria such as lactobacilli in the vagina allows other pathogenic bacteria to multiply in large numbers. The reproduction of anaerobic bacteria also produces amines, which alkalize the vagina, increase vaginal secretions, and produce odor. The resulting common symptoms such as vulvar itching, burning, swelling and pain, vaginal congestion, excessive leucorrhea, and lower abdominal pain bring great inconvenience to normal life and work.

[0003] Common clinical vaginitis mainly includes simple bacterial vaginitis, simple Candida infection, Trichomonas infection, mixed infection and atrophic / senile vaginitis. The action of bacteria and other pathogens in the vagina can cause damage to the vaginal mucosa, resulting in a long treatment cycle or difficulty in eradication. Among the current solutions, most products on the market are designed to inhibit bacteria and reduce inflammation, and cannot repair the vaginal mucosa. Most of the drugs are hormones, some of which have certain side effects and drug resistance; most products on the market have poor healing effects or are prone to recurrence, and there are also certain safety issues. Summary of the invention

[0004] The present invention aims to solve at least one of the technical problems existing in the above-mentioned prior art. To this end, the present invention provides a composition for vaginal repair.

[0005] The invention also provides a method for preparing the composition.

[0006] The invention also provides an application of the composition.

[0007] According to a first aspect of the present invention, a composition for vaginal repair is provided, comprising, by weight, 0.5 to 3 parts of yeast β-glucan, 0.2 to 1 parts of isomaltooligosaccharide and 0.1 to 0.8 parts of sodium hyaluronate;

[0008] The yeast β-glucan includes low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan and high molecular weight yeast β-glucan;

[0009] The molecular weight of the low molecular weight yeast β-glucan is <10 WDa;

[0010] The molecular weight of the medium molecular weight yeast β-glucan is 10WDa~80WDa;

[0011] The molecular weight of the high molecular weight yeast beta glucan is >80 WDa.

[0012] The present invention rationally combines and co-encapsulates three yeast β-glucans of different molecular weights (low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan and high molecular weight yeast β-glucan), and has an outstanding comprehensive effect. The low molecular weight yeast β-glucan can effectively penetrate into the epidermis and dermis tissues and stay in the tissues for a long time; the medium molecular weight yeast β-glucan enters the epidermis layer of the skin to maintain and retain moisture; the high molecular weight yeast β-glucan and oligomaltose are evenly covered on the stratum corneum of the skin to form a protective film, strengthen the skin barrier function, isolate external environmental microorganisms, promote cell regeneration and repair, enhance the elasticity and health of vaginal tissue, and repair the vaginal mucosa.

[0013] According to some embodiments of the present invention, the addition mass ratio of the low molecular weight yeast β-glucan, the medium molecular weight yeast β-glucan and the high molecular weight yeast β-glucan is (1-6): (1-5): (2-6).

[0014] According to some embodiments of the present invention, the added mass ratio of the low molecular weight yeast β-glucan, the medium molecular weight yeast β-glucan and the high molecular weight yeast β-glucan is 3:2:5.

[0015] According to some embodiments of the present invention, the yeast β-glucan has a β-1,3-linked main chain, and contains 1-2 β-1,6-linked glucose side chains on average for every 3-7 main chain glucose residues.

[0016] According to some embodiments of the present invention, the total mass of the yeast β-glucan accounts for 0.5% to 2% of the mass of the composition.

[0017] According to some embodiments of the invention, the composition further comprises water.

[0018] According to some embodiments of the present invention, the composition further comprises 0.1 to 20 parts of auxiliary materials.

[0019] According to some embodiments of the present invention, the composition further comprises 1 to 10 parts of auxiliary materials.

[0020] According to some embodiments of the present invention, the auxiliary material includes at least one of a preservative, a thickener, a wetting agent, and a humectant.

[0021] According to some embodiments of the present invention, the composition further comprises 0.1 to 0.5 parts of a preservative.

[0022] Furthermore, the preservative includes at least one of sodium methylparaben, benzoic acid, sodium benzoate, phenoxyethanol, sorbic acid or sodium sorbate; preferably sodium methylparaben.

[0023] According to some embodiments of the present invention, the composition further comprises 1 to 10 parts of a thickener.

[0024] Furthermore, the thickener includes at least one of carbomer or water-soluble chitosan; preferably carbomer; the carbomer is selected from at least one of carbomer 940, carbomer 941, and carbomer 934.

[0025] The second aspect of the present invention provides a method for preparing the above-mentioned composition, comprising the following steps: mixing the above-mentioned components to obtain the composition.

[0026] The second aspect of the present invention provides the use of the above composition, wherein the use is use in preparing a product for treating gynecological diseases.

[0027] According to some embodiments of the present invention, the application is application in preparing a product for vaginal repair.

[0028] According to some embodiments of the present invention, the vaginal repair includes vaginal mucosal repair and vaginal elasticity repair.

[0029] According to some embodiments of the present invention, the application is application in preparing a product for treating vaginitis.

[0030] The fourth aspect of the present invention provides a product comprising the above composition, wherein the product is used for vaginal repair.

[0031] According to some embodiments of the present invention, the products include medicines and medical devices.

[0032] According to some embodiments of the present invention, the drug further comprises a pharmaceutically acceptable excipient;

[0033] Furthermore, the auxiliary materials include at least one of a diluent, a filler, a binder, an absorption enhancer, a surfactant, an adsorption carrier, a lubricant, and a flavoring agent.

[0034] The diluent may be commonly used in the art, including at least one of calcium sulfate, calcium bicarbonate, and calcium carbonate; the filler may be commonly used in the art, including at least one of starch, sucrose, and lactose; the binder may be commonly used in the art, including at least one of cellulose derivatives, alginate, gelatin, and polyvinyl pyrrolidone; the absorption promoter may be a quaternary ammonium compound commonly used in the art; the surfactant may be hexadecanol commonly used in the art; the adsorption carrier may be commonly used in the art, including at least one of kaolin or soap clay; the lubricant may be commonly used in the art, including at least one of talc, calcium stearate, magnesium stearate, and polyethylene glycol; the flavoring agent may be commonly used in the art, including at least one of rose oil, rose essence, lemon oil, lemon essence, vanilla essence, vanillin, banana essence, pineapple essence, mint oil, orange peel oil, and apple essence.

[0035] According to some embodiments of the present invention, the dosage form of the drug is a gel, a cream, a solution, a spray, a patch, a powder, an ointment, drops, a suppository, a lozenge, a granule, a patch, a capsule, a tablet, or a pill.

[0036] According to some embodiments of the invention, the medical device is a gel.

[0037] According to some embodiments of the present invention, at least the following beneficial effects are achieved: the composition for vaginal repair prepared by the present invention, by using food-grade raw materials, can effectively treat vaginal inflammation, repair vaginal mucosa, and restore vaginal elasticity through specific synergistic effects. Among them, by combining low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan, high molecular weight yeast β-glucan and oligomaltose, cell regeneration and repair are promoted, the elasticity and health of vaginal tissue are enhanced, and vaginal mucosa is repaired; sodium hyaluronate keeps the vaginal mucosa moist, reduces inflammation and discomfort, and promotes the repair and healing of vaginal mucosa. The vaginal repair composition prepared by the present invention can be efficiently used for the treatment of gynecological diseases, and has obvious effects on the treatment of various gynecological diseases such as vaginitis, cervical erosion, vaginal mucosal repair, and vaginal elasticity repair. DETAILED DESCRIPTION

[0038] The following will be combined with the embodiments to clearly and completely describe the concept of the present invention and the technical effects produced, so as to fully understand the purpose, characteristics and effects of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of them. Based on the embodiments of the present invention, other embodiments obtained by those skilled in the art without creative work are all within the scope of protection of the present invention.

[0039] Unless otherwise specified, the experimental methods used in the examples are all conventional methods; the materials and reagents used, unless otherwise specified, are all reagents and materials available from commercial sources.

[0040] The yeast beta-glucan used in the present invention has a beta-1,3-linked main chain and contains 1 to 2 beta-1,6-linked glucose side chains on every 3 to 7 main chain glucose residues.

[0041] Example 1 Preparation of yeast β-glucans of different molecular weights

[0042] In this example, yeast β-glucans with different molecular weights were prepared. The specific process was as follows:

[0043] Take an appropriate amount of commercially available yeast β-glucan, dissolve it in purified water, shake well to obtain a yeast β-glucan solution of about 40 mg / mL, and filter it through a 0.22 μm filter membrane.

[0044] The swelled chromatography filler was loaded into the column, and the column was pressed by purification until the column uniformity met the requirements; after the column was loaded, 3-5 times the column volume of pure water was used to balance the chromatography column. After the chromatography column was balanced, the sample was loaded, and the loading concentration was 40 mg / mL. Pure water was used for elution, 50 mL of the first collected eluate was discarded, and then the eluate was collected step by step, and its molecular weight distribution was determined by high-performance gel permeation chromatography. The eluates with consistent polysaccharide molecular weight distribution were combined, concentrated and freeze-dried. Low molecular weight yeast β-glucan with a molecular weight of <10 WDa, medium molecular weight yeast β-glucan with a molecular weight of 10 WDa~80 WDa, and high molecular weight yeast β-glucan with a molecular weight of >80 WDa were prepared respectively.

[0045] Example 2

[0046] In this embodiment, a composition for vaginal repair is prepared, which includes the following components, by weight: 0.3% low molecular weight yeast β-glucan, 0.2% medium molecular weight yeast β-glucan, 0.5% high molecular weight yeast β-glucan, 0.6% isomaltooligosaccharide, 0.5% sodium hyaluronate, 4% carbomer 941 and 0.2% sodium methylparaben, and the balance is water.

[0047] The preparation method is as follows:

[0048] (1) Add carbomer 941 to a portion of purified water according to the mass percentage ratio while stirring continuously, and stir to completely dissolve the carbomer to obtain solution A;

[0049] (2) Transferring solution A into a vacuum emulsification tank, adding the remaining purified water into the vacuum emulsification tank, stirring and vacuum degassing, to obtain a mixture B;

[0050] (3) After mixture B is completely dissolved, wipe and disinfect the feeding port of the vacuum emulsification tank with alcohol, and turn on the ozone generator to disinfect the emulsification environment for 30 to 40 minutes;

[0051] (4) After disinfection, allow the mixture to ventilate naturally, then add low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan, high molecular weight yeast β-glucan, isomaltooligosaccharide, sodium hyaluronate, and sodium methylparaben. Continue stirring for 30 to 35 minutes and vacuum degassing until the product in the vacuum emulsification tank is bubble-free and transparent. Take an appropriate amount of sample and test the pH value, which should be controlled at 6.5 to 7.5. Cool to room temperature.

[0052] Example 3

[0053] In this embodiment, a composition for vaginal repair is prepared, which includes the following components, by weight: 0.2% low molecular weight yeast β-glucan, 0.3% medium molecular weight yeast β-glucan, 0.5% high molecular weight yeast β-glucan, 0.6% isomaltooligosaccharide, 0.4% sodium hyaluronate, 4% carbomer 941 and 0.2% sodium methylparaben, and the balance is water.

[0054] The preparation method is consistent with that in Example 2.

[0055] Example 4

[0056] In this embodiment, a composition for vaginal repair is prepared, which includes the following components, by weight: 0.4% low molecular weight yeast β-glucan, 0.3% medium molecular weight yeast β-glucan, 0.3% high molecular weight yeast β-glucan, 0.7% isomaltooligosaccharide, 0.4% sodium hyaluronate, 4% carbomer 941 and 0.2% sodium methylparaben, and the balance is water.

[0057] The preparation method is consistent with that in Example 2.

[0058] Example 5

[0059] In this embodiment, a composition for vaginal repair is prepared, which includes the following components, by weight: 0.3% low molecular weight yeast β-glucan, 0.4% medium molecular weight yeast β-glucan, 0.3% high molecular weight yeast β-glucan, 0.8% isomaltooligosaccharide, 0.6% sodium hyaluronate, 4% carbomer 941 and 0.2% sodium methylparaben, and the balance is water.

[0060] The preparation method is consistent with that in Example 2.

[0061] Comparative Example 1

[0062] This comparative example prepares a composition for vaginal repair, which is different from Example 2 only in that it does not contain low molecular weight yeast β-glucan.

[0063] The preparation method is consistent with that in Example 2.

[0064] Comparative Example 2

[0065] This comparative example prepares a composition for vaginal repair, which is different from Example 2 only in that it does not contain medium molecular weight yeast β-glucan.

[0066] The preparation method is consistent with that in Example 2.

[0067] Comparative Example 3

[0068] This comparative example prepares a composition for vaginal repair, which is different from Example 2 only in that it does not contain high molecular weight yeast β-glucan.

[0069] The preparation method is consistent with that in Example 2.

[0070] Comparative Example 4

[0071] This comparative example prepares a composition for vaginal repair, which is different from Example 2 only in that it does not contain isomaltooligosaccharide.

[0072] The preparation method is consistent with that in Example 2.

[0073] Comparative Example 5

[0074] This comparative example prepares a composition for vaginal repair, which is different from Example 2 only in that it does not contain sodium hyaluronate.

[0075] The preparation method is consistent with that in Example 2.

[0076] Comparative Example 6

[0077] This comparative example prepares a composition for vaginal repair, which is different from Example 2 only in that it does not contain low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan and high molecular weight yeast β-glucan.

[0078] The preparation method is consistent with that in Example 2.

[0079] Comparative Example 7

[0080] This comparative example prepares a composition for vaginal repair, which is different from Example 2 only in that 0.3% of low molecular weight yeast β-glucan, 0.2% of medium molecular weight yeast β-glucan, and 0.5% of high molecular weight yeast β-glucan are replaced with 1% of shiitake mushroom β-glucan.

[0081] The preparation method is consistent with that in Example 2.

[0082] Comparative Example 8

[0083] This comparative example prepares a composition for vaginal repair, which is different from Example 2 only in that 0.3% of low molecular weight yeast β-glucan, 0.2% of medium molecular weight yeast β-glucan, and 0.5% of high molecular weight yeast β-glucan are replaced with 1% of oat β-glucan.

[0084] The preparation method is consistent with that in Example 2.

[0085] Test Case

[0086] 1. Safety testing

[0087] For Example 2, experimental rabbits were used to conduct vaginal mucosal irritation tests according to the toxicological safety test GB15979-2002. Five healthy, adult female rabbits were selected and divided into an experimental group (3) and a blank control group (2). The experimental group was treated with the vaginal repair composition prepared in Example 2, and the blank control group was treated with an equal amount of pure water. Vaginal administration was performed once a day for 7 consecutive days, and the animals were killed 24 hours after the last administration. Observation content: clinical manifestations of rabbits (such as pain symptoms), vaginal secretions (such as blood, mucus), animal death and autopsy after each administration; after the animals were killed, whether the local tissues had congestion, edema and other phenomena, and vaginal pathological histology was performed. As a result, the mental state of the rabbits in the experimental group and the blank control group was normal, and there was no mucus or bleeding in the vagina; after dissection, the vaginal mucosa of the rabbits in the experimental group and the blank control group was smooth and ruddy, without congestion, edema, erosion and other phenomena, and the vaginal epithelial cells were intact and without pathological histological changes. The experimental results show that the vaginal repair composition has no irritation to the vaginal mucosa.

[0088] 2. In vitro antibacterial test

[0089] The Candida albicans, Staphylococcus aureus and Escherichia coli in this test example were purchased from Ningbo Mingzhou Biotechnology Co., Ltd.

[0090] (1) Screening of antibacterial agents: The filter paper method was used. Three pathogenic bacteria that are prone to vaginitis, Candida albicans, Staphylococcus aureus, and Escherichia coli, were selected, and the size of the inhibition zone was used as an indicator.

[0091] (2) Preparation of bacterial suspension: Staphylococcus aureus and Escherichia coli were inoculated on a slant nutrient medium and cultured at 30°C for 24 h; Candida albicans was inoculated on a slant Sabouraud medium and cultured at 30°C for 48 h. The bacterial mosses were washed off with sterile PBS and the concentration was adjusted to 3×10 8 CFU / mL, for future use.

[0092] (3) Preparation of drug-containing filter paper: Take sterile dry filter paper, punch 6 mm holes with a puncher, and soak them in 50 mL of sterile physiological saline containing equal amounts of the composition for vaginal repair prepared in Examples 2-5 and Comparative Examples 1-8 for 15 min for use.

[0093] Antibacterial activity assay:

[0094] Add 100 μL of the prepared strain suspension to 4 sterile culture dishes, and then pour in a 40°C sterile culture medium and mix evenly. After solidification, use sterile tweezers to pick up each drug-containing filter paper (containing the drug filter paper of Examples 2-5 and Comparative Examples 1-8, respectively), place it 15 mm away from the edge of the culture dish, and press gently to make the filter paper close to the culture medium. Repeat each 3 times. Place the culture dish upside down in a 30°C constant temperature incubator and culture for 24 and 48 hours respectively, then observe whether there is an antibacterial zone around the drug-containing filter paper, and determine its antibacterial diameter (including the paper diameter) by the cross method. Repeat each measurement 3 times and take the average value.

[0095] Table 1

[0096]

[0097] The experimental results are shown in Table 1. It can be seen from the table that the composition for vaginal repair prepared in the embodiment of the present invention has significantly better effects on Staphylococcus aureus, Escherichia coli and Candida albicans than the control example. The results show that β-glucans of different molecular weights have a synergistic effect with oligomaltose and sodium hyaluronate in the antibacterial effect on bacteria.

[0098] 3. Animal experiments

[0099] (1) Treatment test of mixed vaginitis in mice

[0100] The mice of the present invention were purchased from Ningbo Mingzhou Biotechnology Co., Ltd.

[0101] 1) Modeling: 35 healthy mice were subcutaneously injected with 0.5 mg / mouse estradiol benzoate injection on the third day before administration (every morning), and streptomycin 50 μg / mouse / time was injected into the vagina of rats. Then, mixed bacteria (Gardnerella, Candida albicans, and group B Streptococcus suspension (1:1:1 colony count)) were injected into the vagina (1×10 8CFU / mL) 50μL / mouse / time, once a day, for 3 consecutive days. The mixed vaginitis model was replicated, and 50μL of PBS without strains was inoculated into the vagina of the blank group mice (5 mice). 50μL of sterile PBS was injected into the vagina of the model group and the blank group mice before grouping. The washing fluid (about 250μL) was sucked out after gently blowing 5 times with a pipette, and 50μL was taken for observation under a microscope. It was found that the mixed infection rate was 92.1% on the 5th day of administration, the number of pathogenic colonies increased significantly, the negative conversion rate of vaginal secretion smear decreased significantly, the cleanliness score increased significantly, and the vaginal pH increased significantly. Its abnormal symptoms were similar to the clinical manifestations of vaginitis, indicating that the model was successfully constructed.

[0102] 2) Model treatment validation:

[0103] After successful modeling, 7 medication treatments were performed, and the mice with successful modeling were divided into 7 groups, 5 mice in each group, and the medical absorbable gelatin sponges were cut into 0.5 cm × 0.5 cm sizes, and the vaginal repair compositions prepared in Example 2 and Comparative Examples 1-6 were applied respectively, and then placed in the vagina of the mice respectively; after 7 days of treatment recovery, 50 μL of sterile PBS was injected into the vagina of the mice, and the washing liquid (about 250 μL) was sucked out after gently blowing 5 times with a pipette, and 50 μL was taken for observing the number of colonies under a microscope. The results are shown in Table 2 below.

[0104] Table 2

[0105]

[0106] The experimental results are shown in Table 2. It can be seen from the table that the composition for vaginal repair prepared in Example 2 can effectively inhibit the activity of pathogenic bacteria. The results of Comparative Examples 1-6 show that β-glucans with different molecular weights have a synergistic effect with oligomaltose and sodium hyaluronate on the antibacterial effect of bacteria, which can significantly improve the therapeutic effect of vaginitis.

[0107] (2) Mucosal transdermal absorption test

[0108] 15 healthy mice that have been adapted to the breeding environment in the laboratory were subcutaneously injected with 0.05 mL of 0.1 mg estradiol benzoate oil starting 6 days before inoculation, and then injected once every 2 days. The isolated and purified Candida albicans was inoculated in a liquid culture medium containing 1% peptone and 0.1% glucose, and cultured in a 25°C water bath with shaking for 16-18 hours. When inoculating, the density of 2.5×10 6 / L of bacterial suspension dissolved in PBS 20μL (i.e., the inoculum size of Candida albicans spores is 5×10 4 The 50 μg / ml 200 μg / ml 400 μg / ml 200 μg / ml was injected into the vagina of mice on the inoculation day to prepare the Candida albicans vaginitis model in the model group mice.

[0109] Vaginitis was induced from the day of inoculation, and vaginitis caused damage to the vaginal mucosa. After 5 days of inoculation, it was confirmed that the vaginal mucosa was obviously damaged. The mice with successful modeling were divided into 4 groups, each with 3 mice. The same amount of the composition for vaginal repair prepared in Examples 2-5 was respectively injected into the vagina of each group of mice. After the insertion, the mice were raised normally. At 0.5 hours, 5 mice in each group were killed, the test tissue site was excised and cleaned, and the β-glucan in the washing solution was quantitatively analyzed by HPLC-differential refractometry (the sample processing method refers to QB / T 4572-2013), which is the β-glucan and mannan that failed to penetrate the skin.

[0110] The formula for calculating the transdermal rate is: transdermal rate = (the total amount of injected polysaccharide - the amount of polysaccharide that failed to penetrate the skin) / the total amount of injected polysaccharide. The experiment was repeated 3 times and the average value was taken.

[0111] Table 3

[0112]

[0113] The experimental results are shown in Table 3. It can be seen from the table that the vaginal repair composition prepared in Example 2 of the present application has the best skin permeability test result. The results show that the ratio of yeast β-glucan with different molecular weights has a synergistic effect on the repair of vaginal mucosa.

[0114] 4. Clinical trials

[0115] (1) Test on the efficacy of repairing vaginitis

[0116] 60 married women aged 20-40 with vaginitis were randomly selected, all of whom were informed consent patients, and randomly divided into 20 groups: each group was used with the same amount (about 3 mL) of the vaginal repair composition prepared in Example 2 and Comparative Example 6 and the commercially available vaginitis repair gel for experiments, twice a day, and the test results were observed after 5 days:

[0117] Table 4

[0118]

[0119] It can be seen from Table 4 that the vaginal repair composition prepared in Example 2 has a more significant effect on the repair of vaginitis and has a more stable effect than commercially available gynecological gels.

[0120] (2) Vaginal elasticity test

[0121] 20 women aged 20-40 with postpartum vaginal relaxation were randomly selected for the test. All of them were informed consent volunteers. They were randomly divided into groups of 10 volunteers in each group. The same amount (about 3 mL) of the composition prepared in Example 2, the composition prepared in Comparative Example 6 and the commercially available gynecological gel were used for the experiment. The test results were observed after 14 days of use.

[0122] Table 5

[0123]

[0124] The results are shown in Table 5. The compositions for vaginal repair prepared by the present invention can quickly restore vaginal elasticity without rebound.

[0125] The yeast β-glucan, isomaltooligosaccharide and sodium hyaluronate used in the examples and comparative examples of the present invention are all conventional products available on the market.

[0126] The above is a detailed description of the embodiments of the present invention, but the present invention is not limited to the above embodiments. Various changes can be made within the knowledge of ordinary technicians in the relevant technical field without departing from the purpose of the present invention. In addition, the embodiments of the present invention and the features in the embodiments can be combined with each other without conflict.

Claims

1. A composition for treating vaginitis and restoring vaginal elasticity, characterized in that: In parts by weight, the composition consists of 0.5 to 3 parts of yeast β-glucan, 0.2 to 1 parts of isomaltooligosaccharide and 0.1 to 0.8 parts of sodium hyaluronate; The yeast β-glucan includes low molecular weight yeast β-glucan, medium molecular weight yeast β-glucan and high molecular weight yeast β-glucan; The molecular weight of the low molecular weight yeast β-glucan is <10 WDa; The molecular weight of the medium molecular weight yeast β-glucan is 10WDa~80WDa; The molecular weight of the high molecular weight yeast β-glucan is >80 WDa; The added mass ratio of the low molecular weight yeast β-glucan, the medium molecular weight yeast β-glucan and the high molecular weight yeast β-glucan is 1-6:1-5:2-6.

2. The composition according to claim 1, characterized in that The yeast β-glucan has a β-1,3-linked main chain, and contains 1 to 2 β-1,6-linked glucose side chains on every 3 to 7 glucose residues in the main chain.

3. A method for preparing the composition according to any one of claims 1 to 2, characterized in that: Mix all the components.

4. Use of the composition according to any one of claims 1 to 2 in the following (1) to (2): (1) Preparation of products for vaginal elasticity repair; (2) Preparation of products for the treatment of vaginitis.

5. A product, characterized in that: The invention comprises the composition according to any one of claims 1 to 2; the product is used for treating vaginitis and restoring vaginal elasticity.

6. The product according to claim 5, characterized in that The products include medicines and medical devices.

Citation Information

Patent Citations

  • Chemical substance for treating colpitis

    CN101411714A

  • Traditional Chinese medicine composition gel for relieving gynecologic inflammation and contracting vagina and preparation technology thereof

    CN107661494A

  • Biogel dressing for preventing / treating HPV and gynecologic inflammations as well as preparation method and application of biogel dressing

    CN112315899A

  • Gynecological gel as well as preparation method and application thereof

    CN113730433A

  • Composition as well as preparation method and application thereof

    CN115501246A